Organism: Homo sapiens
Gene: 38487_at
Selected probe(set): 38487_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38487_at (38487_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):4.690648
Number of Samples:36 / 74

Experimental	AML study 1 (t(15;17)(q22;q11-12))
	Bone marrow samples of patients with acute promyelocytic leukemia [subtype of acute myeloid leukemia (AML)] with genetic aberration (t(15;17)(q22;q11-12)/PML-RARα and variations).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):3.7502575
Number of Samples:5 / 5

Experimental	monocyte activation study 1 (NOD2L/TLR/1L; 24h)
	Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control	monocyte activation study 1 (NOD2L/TLR/1L; 6h)
	Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).

Relative Expression (log2-ratio):3.6127434
Number of Samples:2 / 4

Experimental	glioma study 17 (glioblastoma; unsorted)
	Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control	non-tumor cortical tissue
	Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

Relative Expression (log2-ratio):3.5295916
Number of Samples:2 / 4

Experimental	glioma study 17 ( small cell glioblastoma; unsorted)
	Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males.
Control	non-tumor cortical tissue
	Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

Relative Expression (log2-ratio):-3.5067015
Number of Samples:2 / 2

Experimental	C. pneumoniae study 1
	Monocyte-derived dendritic cells from healthy donors were infected with Chlamydia pneumoniae at a multiplicity of infection of 5 for 72 h.
Control	uninfected monocyte-derived dendritic cell sample
	Uninfected monocyte-derived dendritic cells from healthy donors.

Relative Expression (log2-ratio):3.4668121
Number of Samples:5 / 5

Experimental	monocyte activation study 1 (TLR/1L; 24h)
	Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control	monocyte activation study 1 (TLR/1L; 6h)
	Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).

Relative Expression (log2-ratio):-3.4327717
Number of Samples:3 / 3

Experimental	VTX-2337 study 1
	Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control	untreated monocyte sample
	Peripheral blood monocytes isolated from healthy donors.

Relative Expression (log2-ratio):-3.1742163
Number of Samples:2 / 2

Experimental	IFN-g; LPS study 1
	Monocytes LPS/IFN-g activated for 30h.
Control	normal resting monocyte sample
	Monocytes resting for 30h.

Relative Expression (log2-ratio):-3.1664085
Number of Samples:3 / 3

Experimental	VTX-2337 study 1
	Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control	3M-055 study 1
	Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM 3M-055 drug, which represents a TLR7 (Toll-like receptor 7) agonist.

Relative Expression (log2-ratio):-3.125988
Number of Samples:4 / 6

Experimental	F. tularensis study 1 (novicida)
	Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control	uninfected peripheral blood monocyte sample
	Peripheral blood monocytes uninfected.